Successful Experience of Fecal Transplantation in a Patient with Severe Pseudomembranous Colitis

Introduction. At the present time there is increase the number of patients diagnosed with pseudomembranous colitis due to Clostridiodes difficile, respectively it significantly increases the frequency of hospitalizations, the length of hospital stay and the cost of treatment. Approved drug methods for correcting a  pathological condition are not always able to lead to recovery after the first use, repeated and prolonged courses of therapy are often required, especially with recurrent Clostridiodes difficile. An alternative way of treatment is fecal microbiota transplantation from a donor. Nowadays, fecal microbiota transplantation is included in national clinical guidelines in several countries in Europe, the USA and Australia. In Russia this method has not been registered, however, there are some publications about its successful application in gastrointestinal diseases, oncohematology, and some autoimmune diseases.

Aim. To show the result of successful treatment of severe pseudomembranous colitis after a single fecal microbiota transplantation.

Material and methods. Outpatient treatment of an acute respiratory infection with a broad-spectrum antibacterial drug caused the development of severe pseudomembranous colitis in a young patient. Standard courses of metronidazole and vancomycin were unsuccessful. Transplantation of fecal microbiota from a donor was performed via ileocolonoscopy.

Results. A single fecal microbiota transplantation contributed to the patient’s complete recovery, short term  rehabilitation and the absence of recurrence of Clostridiodes difficile within two years. Conclusions. Evidence-based medicine has shown the high efficiency of fecal microbiota transplantation. In Russia a legislative basis is needed for including fecal microbiota transplantation in clinical guidelines for the treatment of severe Clostridiodes difficile resistant to standard therapy.

1. Lessa F, Mu Y, Bamberg W, Beldavs Z, Dumyati G, Dunn J, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015; 372: 825-834. doi: 10.1056/NEJMoa1408913

2. Knight D, Elliott B, Chang B, Perkins T, Riley T. Diversity and evolution in the genome of Clostridium difficile. Clin Microbiol Rev. 2015; 28(3): 721-741. doi: 10.1128/CMR.00127-14

3. Ivashkin VT, Yushchuk ND, Maev IV, Lapina TL, Poluektova EA, Shifrin OS, et al. Recommendations of the Russian Gastroenterological Association for the diagnosis and treatment of Clostridium difficile-associated disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016; 26(5): 56- 65. doi: 10.22416/1382-4376-2016-26-5-56-65. (In Russ.)

4. Shelygin YuA, Aleshkin VA, Sukhina MA, Mironov AYu, Briko NI, Kozlov RS, et al. Clinical guidelines of the National Association of Specialists in Control of Medical Care-Associated Infections and the Association of Coloproctologists of Russia for the diagnosis, treatment and prevention of Clostridium difficile-associated diarrhea. Koloproktologia. 2018; 3(65): 7-23. (In Russ.)

5. Momani L, Abughanimeh O, Boonpheng B, Gabriel J, Young M. Fidaxomicin vs vancomycin for the treatment of a first episode of Clostridium difficile infection: a meta-analysis and systematic review. Cureus. 2018; 10(6): e2778. doi: 10.7759/cureus.2778

6. Aziz M, Weissman S, Rajani FR, Eid A, Nawras A. Cadazolid vs vancomycin for the treatment of Clostridioides difficile infection: systematic review with meta-analysis. Curr Clin Pharmacol. 2020; 15(1): 4-10. doi: 10.2174/1574884714666190802124301

7. Surawicz C, Brandt L, David G, Ananthakrishnan A, Curry S, Gilligan P, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013; 108(4): 478-498. doi: 10.1038/ajg.2013.4

8. Sokol H, Galperine T, Kapel N, Bourlioux P, Seksik P, Barbut F, et al. Faecal microbiota transplantation in recurrent Clostridium difficile infection: Recommendations from the French Group of Faecal Microbiota Transplantation. Dig Liver Dis. 2016; 48(3): 242-247. doi: 10.1016/j.dld.2015.08.017

9. Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M, Kump P, Satokari R, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017; 66: 569-580. doi: 10.1136/gutjnl-2016-313017

10. Kelly C, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A. Update on fecal microbiota transplantation2015: indications, methodologies, mechanisms, and outlook. Gastroenterology. 2015; 149(1): 223-237. doi: 10.1053/j.gastro.2015.05.008

11. Van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013; 368: 407-15. doi: 10.1056/NEJMoa1205037

12. Cammarota G, Masucci L, Ianiro G, Bibbò S, Dinoi G, Costamagna G, et al. Randomized clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015; 41: 835-843. doi: 10.1111/apt.13144

13. Goloshchapov OV, Churakina DV, Kucher MA, Klementyeva RV, Sidorenko SV, Gostev VV, et al. Fecal microbiota transplantation in critical condition of patients in oncohematological practice. Messenger of Anesthesiology and Resuscitation. 2019; 3(16): 63-73. doi: 10.21292/2078-5658-2019-16-3-63-73. (In Russ.)

14. Shrainer EV, Morozov VV, Khavkin AI, Vlasov VV, Kulikov VG, Koltsova ST. Experience of fecal microbiota transplantation in a patient with clostridial infection. Experimental and Clinical Gastroenterology. 2018; 12(160): 80-83. doi: 10.31146/1682-8658-ecg-160-12-80-83. (In Russ.)

15. Shcherbakov PL, Belova ND, Generozov EV, Zhgun ES, Ivanova IO, Ilyina EN, et al. Using fecal transplantation in the treatment of digestive tract diseases (first clinical experience). Doctor.Ru. 2019; 3(158): 40-46. doi: 10.31550/1727-2378-2019-158-3-40-46(In Russ.)

16. Karpukhin OYu, Khasanov ER, Bikbov BSh. Fecal microbiota transplantation in modern clinical practice. Practical Medicine. 2017; 6(107): 7-12. (In Russ.)

17. Apartsin KA, Kulundukov AA, Chashkova EYu. Device for preparing donor fecal material for transplantation: Patent N 2659417 of the Russian Federation. (In Russ.)